Lack of Significant Skeletal Changes after Long-Term, Low-Dose Retinoid Therapy: Case Report and Review of the Literature

@article{Halverstam2006LackOS,
  title={Lack of Significant Skeletal Changes after Long-Term, Low-Dose Retinoid Therapy: Case Report and Review of the Literature},
  author={Caroline P. Halverstam and Joshua A. Zeichner and Mark G. Lebwohl},
  journal={Journal of Cutaneous Medicine and Surgery},
  year={2006},
  volume={10},
  pages={291 - 299}
}
Background: Long-term systemic retinoid therapy has been associated with skeletal side effects. There have been reports of diffuse idiopathic skeletal hyperostosis (DISH) syndrome, calcification of ligaments, and osteoporosis, as well as premature fusion of epiphyses and modeling abnormalities of long bones, occurring in patients on chronic high-dose isotretinoin, etretinate, and acitretin therapy. Low-dose acitretin has been used for many years as monotherapy or in combination with other… Expand
Musculoskeletal Symptoms with Long-term Acitretin Therapy for Psoriasis: An Age- and Sex-matched Retrospective Study
TLDR
It is identified that there is no increase in the incidence of musculoskeletal symptoms between patients with psoriasis who have taken long-term acitretin, and patients who have never taken acitretsin. Expand
Generalized Pustular Psoriasis in a Child: Observation of Long‐Term Combination Therapy with Etretinate and Calcipotriol for 16 Years
TLDR
The long‐term course of a 3‐year‐old boy whose onset of psoriasis dated to age 7 months is reported, without evidence of stunted growth, ligamentous calcification, hyperostosis, or hepatic toxicity. Expand
Management of pediatric psoriasis with acitretin: A review
TLDR
Using acitretin in a low dose and with proper physical examinations and laboratory investigations will reduce the hazard of potential serious adverse events and retinoids are probably the second line drugs for the treatment of pediatric psoriasis which do not respond to topical therapies and phototherapy. Expand
Systemic Treatment of Pediatric Psoriasis: A Review
TLDR
This review focuses on the use of systemic treatments in pediatric Psoriasis and their specific features, analyzing the few literature evidences available, expanding the treatment repertoire and guiding dermatologists in better managing of recalcitrant pediatric psoriasis. Expand
Case Report: Psoriatic Erythroderma with Bilateral Osseous Bridge Across the Acetabulum
TLDR
This is the first report of an osseous bridge associated with long-term administration of etretinate extending across the acetabulum over the femur on both sides, and the patient experienced a major gait disturbance and eventually was unable to walk. Expand
Biochemical and histopathologic assessment of effects of acitretin on epiphyseal growth plate in rats
TLDR
The data show that though acitretin caused degeneration of the epiphyseal plate, it did not cause clear thinning and the authors identified no significant variations in bone metabolism markers. Expand
Retinoids, methotrexate and cyclosporine.
Acitretin alone is efficient (PASI 90: 40%). In responders, it is the best long-term maintenance treatment (up to 29 years of continuous treatment). The main side effect is its teratogenicity inExpand
Management of childhood psoriasis.
TLDR
Treating children with psoriasis represents one of the most rewarding yet constantly challenging endeavors in dermatology; partner with the patient, family, and other multidisciplinary providers to form an educational and therapeutic alliance. Expand
Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis
TLDR
Both conventional and biologic treatments are effective in the treatment of psoriasis, but they are associated with serious adverse events, ranging from organ toxicity to serious infections, birth defects, and malignancies. Expand
A Practical Approach to the Use of Acitretin for the Treatment of Psoriasis
TLDR
A practical approach to the use of acitretin in the treatment of psoriasis is outlined, which shows that this medication works primarily by enhancing differentiation and maturation of cells and can be used for long-term maintenance therapy or in combination with other topical or systemic agents and phototherapy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 38 REFERENCES
Association between long‐term acitretin therapy and osteoporosis: no evidence of increased risk
TLDR
Osteoporosis has been observed with chronic hypervitaminosis A, leading some authors to hypothesize that systemic retinoids may have an effect on bone mineral density, and acitretin appears to be safe for long‐term use in patients with chronic dermatoses. Expand
Single‐center retrospective study of long‐term use of low‐dose acitretin (Soriatane®) for psoriasis
  • E. Lee, J. Koo
  • Medicine
  • The Journal of dermatological treatment
  • 2004
TLDR
Akitretin does not appear to cause significant long‐term side effects at low doses; the implications for thousands of patients are that use of this medication can be continued for long periods of time with routine monitoring. Expand
Bone X‐ray examinations in patients treated with isotretinoin: a prospective study
TLDR
A prospective radiological study of the effects of 4 months' treatment with moderate doses of isotretinoin concludes that retinoid treatment given for this duration and in the stated dosage may be considered safe from the point of view of the skeletal system. Expand
Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne.
TLDR
A 16- to 20-week course of isotretinoin treatment at the recommended dose for severe acne has no clinically significant effect on lumbar spine and total hip BMD in the adolescent (12-17 years) population. Expand
Long-term radiographic follow-up after isotretinoin therapy.
TLDR
In a group of nine patients who received a relatively high dose of isotretinoin in 1982 for the treatment of acne, two patients developed tiny, asymptomatic hyperostoses, which should not be of concern for the patient needing routine isotretinosin therapy for the Treatment of cystic acne. Expand
Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities
TLDR
All records of patients who underwent spinal radiographs at the request of the department of dermatology between 1983 and 1993 were reviewed and a group of 135 patients comprised the total population of retinoid‐treated patients and those patients who were investigated for possible future retinoids treatment. Expand
Osteoporosis is a toxic effect of long-term etretinate therapy.
TLDR
This cross-sectional study identified osteoporosis in patients who received long-term therapy with etretinate but not isotretinoin and suggested that prospective studies of BMD would be useful to further define retinoid-associated bone mineral density. Expand
Effects of retinoids in bone.
  • R. Kilcoyne
  • Medicine
  • Journal of the American Academy of Dermatology
  • 1988
TLDR
Because of the extensive amount of preexisting disease in the psoriasis group compared with the relatively normal appearance of the spine in the isotretinoin group, the underlying disease process may be more important than the retinoid therapy. Expand
Skeletal toxicity with isotretinoin therapy: a clinico‐radiological evaluation
TLDR
D doses of 0.5 mg/kg/day isotretinoin in patients with abnormal X‐rays did not produce any significant long‐term musculoskeletal changes, and radiologists and dermatologists should be aware of its skeletal toxicity. Expand
Vertebral abnormalities associated with synthetic retinoid use.
TLDR
It is suggested that the ingestion of isotretinoin at mean total dose of 150,060 mg for an average of 2.9 years is associated with a statistically significant increase in developing an associated ossifying diathesis in patients with BCNS or BCC, when compared with matched, untreated controls. Expand
...
1
2
3
4
...